Rumors of an AstraZeneca-Bristol Myers Squibb megamerger continue to circulate; Amgen becomes latest in list of health companies announcing major data breaches; Michigan reports two deaths in cyclosporiasis outbreak.
Industry eyes have centered on reports of a potential megamerger between AstraZeneca and Bristol Myers Squibb that would value the pharma giants at roughly $400 billion and rank among the largest pharma tie-ups in history. Neither company confirmed the report and analysts question why AstraZeneca would make the move when its value has surged under CEO Pascal Soriot. (CNBC)
Amgen is the latest health company to announce a data breach, joining the likes of Novo Nordisk, Abbott and Medtronic among others. The company said it has not found any impact on products, manufacturing operations, financial reporting systems or its ability to meet patient needs. (Reuters)
Two people in Michigan have died after contracting cyclosporiasis, according to the state Health and Human Services Department. Both people — whose identities were not provided — had “significant underlying health conditions that may have been impacted by cyclosporiasis and dehydration.” (NBC News)
The Sandoz entered a $450 million settlement agreement with 43 U.S. states. The settlement does not impact the company’s full-year 2026 guidance or mid-term outlook. (Bloomberg)
During appointments, many of us have had a physician pull out an artificial intelligence tool to help automate post-visit notetaking. It’s used to help automate and prevent physician burnout. However, medical schools are struggling with whether students should learn to use the tools or go through the thought process to diagnose. (STAT News)
